CELC - Company ID 0001603454
Celcuity Inc. trades as CELC and has a market capitalization of $5.54 B, making it the #1341 largest US-listed company by market value. This page tracks Celcuity Inc. through 506 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-20 |
| Major company event (amended) | 8-K/A | 2026-05-20 |
| Employee stock plan | S-8 | 2026-05-18 |
| Major company event | 8-K | 2026-05-18 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Insider trade | 4 | 2026-05-06 |
Phase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; detailed data for gedatolisib regimens will be presented at the 2026 ASCO Annual Meeting
Development of a gedatolisib formulation for subcutaneous injection is underway; first patent application submitted to the U.S. Patent and Trademark Office
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1760785&tp_key=2f73ec65ba . A replay of the webcast will be available on the Celcuity website following the live event.
Detailed data for the gedatolisib triplet and doublet regimens will be presented at a late-breaking abstract oral session at the 2026 ASCO Annual Meeting
The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription Drug User Fee Act (“PDUFA”) goal date of July 17, 2026, for gedatolisib in HR+/HER2-/PIK3CA wild-type (“WT”) advanced breast cancer (“ABC”)
The largest companies sharing Celcuity Inc.'s SEC industry classification (services-medical laboratories).
Celcuity Inc. (CELC) has a market capitalization of $5.54 B as of 2026-07-09, ranking #1341 among US-listed companies.
In its latest fiscal year Celcuity Inc. reported a net loss of $177.04M.